The human microbiome as a key lever for health and performance
The human microbiome consists of trillions of microorganisms that affect not only the gut, but the health of the entire body and our overall well-being. For example, the gut microbiome affects the immune system, skin, metabolism, and brain far beyond digestion. As more people become aware of the central role the gut microbiome plays in our overall health, there is growing interest in how diet and nutrition can positively influence our microbiome. As a result, there is a growing demand for microbiotic products such as prebiotics and probiotic supplements.
B4U™ - Science‑backed probiotic strains for advanced nutrition applications
Our B4U™ brand of bacterial strains from our extensive strain library allows you to create foods, food supplements or FSMPs (food for special medical purposes) for microbiome health. The health benefits of our probiotics have been scientifically researched and clinically tested in innovative synbiotic combinations. Use our B4U™ quality strains for value-added differentiation of your individual products.
Spore-forming bacterial strains such as from Bacillus subtilis, Bacillus megaterium
Spore formers are very robust, which makes them easy to process. Our spores are suitable for a variety of formulations: as a powder for sports nutrition or dietary supplements, for filling into capsules or for processing into fruit gummies. Their stability ensures long shelf life in products. Spore-forming bacterial cultures are also highly resistant to gastric and bile acids in the digestive tract.
At Evonik, we have many years of experience in the development of spore products, such as spore-based probiotics, and will be happy to advise you.
Our B4U™ microbial strains
Bacillus subtilis, the 2023 Microbe of the Year by the Association for General and Applied Microbiology (VAAM), is a highly versatile and well‑studied microorganism widely used across biotechnology, life sciences, nutrition, agriculture, and industrial applications. As a trusted supplier of Bacillus subtilis solutions, we support our customers with high‑quality strains, tailored products, and deep technical expertise across development and manufacturing.
Known for its robustness, proven safety profile (GRAS status), and broad functional potential, Bacillus subtilis is ideally suited for innovative and sustainable applications. Our capabilities enable customers to harness the full value of this powerful bacterium in a reliable, scalable, and regulatory‑compliant manner. From research to full‑scale production, we are your expert partner for Bacillus subtilis‑based solutions.
Target areas of Bacillus subtilis DSM 32315
- Intestine
- Immune system
- Metabolism
- Gut-brain axis
Strain properties of Bacillus subtilis DSM 32315
- Tested to the EFSA safety standard/QPS status
- Self-affirmed GRAS status for use in foods
- Remarkable heat and process stability/storage stability
- Extraordinary resistance to gastric and bile acid
- Gastric and bile acid resistance
- Inhibitory to many known pathogens
- Produces large amounts of lactic acid
- Causes an increase in butyrate levels in the gut
- Promotes butyrate-forming bacteria
- Enhances beneficial bacteria via cross‑feeding
- Has been clinically studied for its effect on glucose metabolism and lipid levels
The B4U™21 strain was investigated in pre-clinical and clinical studies
- Tom Dieck, H., Schön, C., Wagner, T., Pankoke, H. C., Fluegel, M., & Speckmann, B. (2021)
A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
Nutrients, 14(1), 143 - Kordowski, A., Tetzlaff-Lelleck, V. V., Speckmann, B., Loh, G., Künstner, A., Schulz, F., Schröder, T., Smollich, M., Sina, C., & Tom Dieck, H. (2022)
A nutritional supplement based on a synbiotic combination of Bacillus subtilis DSM 32315 and L-alanyl-L glutamine improves glucose metabolism in healthy prediabetic subjects - A real-life post-marketing study
Frontiers in nutrition, 9, 1001419 - Tom Dieck, H., Tomassi, D., Postrach, E., Ehring, E. (2026)
Effects of targeted colonic synbiotic supplementation with Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine on mental wellbeing: An open-label pilot study
Global Translational Medicine, DOI:10.36922/GTM025460086
Bacillus megaterium is a well‑established microbial production host valued for its large cell size, exceptional genetic stability, and strong performance in industrial biotechnology. As a specialized provider of Bacillus megaterium‑based solutions, we enable efficient development and manufacturing of enzymes, recombinant proteins, and other biologically derived products.
This organism is particularly suited for applications requiring high secretion yields, straightforward downstream processing, and reliable scale‑up. Leveraging our deep process knowledge, robust strain portfolio, and manufacturing expertise, we help customers translate Bacillus megaterium’s biological advantages into commercially viable and regulatory‑ready solutions. We support projects from early development through industrial production with a focus on quality, scalability, and long‑term performance.
Target areas of Bacillus megaterium DSM 32963
- Intestine
- Micro-inflammatory processes
Strain properties of Bacillus megaterium DSM 32963
- Tested to the EFSA safety standard/QPS status
- Self-affirmed GRAS status for use in foods
- Heat and process stability
- Gastric and bile acid resistance
- Specialized pro-resolving mediator (SPM) producer: converts omega-3 fatty acids into anti-inflammatory lipids
- Has been studied in clinical trials for its effect on SPM formation
The B4U™63 strain was investigated in preclinical and clinical studies
- Speckmann et al.
Synbiotic Compositions of Bacillus megaterium and Polyunsaturated Fatty Acid Salt Enable Self Sufficient Production of Specialized Pro-Resolving Mediators
Nutrients. 2022 May 28;14(11):2265 - Speckmann, B., Wagner, T., Jordan, M.P., Werz, O., Wilhelm, M., Tom Dieck, H., Schön, C. (2024)
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study, 16 (9) - Speckmann, B., Jordan, M.P., Werz, O., Hofstetter, R.K., Ehring, E., Vogel, M.-V., Venema, K. (2025)
Bacillus megaterium DSM 32963 Enhances Specialized Pro-Resolving Mediator Production from an n-3 PUFA Salt in a Dynamic Model of the Human Intestine, 15 (2)
Did you know?
We also use our B4U™ quality strains in our innovative synbiotic combinations marketed under IN VIVO BIOTICS™.
Does your company want to bring dietary supplements to the next level? Are you interested in finding out more about our solutions?
Susanne Pluta (Director Consumer Products)
General disclaimer
The content of this website is intended for healthcare professionals and business customers only. This content is not intended for end users of such products. None of the statements on this website should be taken as an approved health claim.
These claims have not been evaluated by EFSA. This product is not intended to diagnose, treat, cure or prevent any disease.
These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure or prevent any disease.